Vaccine Info

Pneumococcal Vaccines

Pneumococcal disease is caused by Streptococcus pneumoniae, a bacterium that has more than 90 serotypes. Only a few of these serotypes produce the majority of invasive pneumococcal disease.

Pneumococcal disease is spread from person to person by droplets in the air. The pneumococci bacteria are common inhabitants of the human respiratory tract.

Pneumococcal pneumonia is the most common disease caused by pneumococcal infection and can occur in combination with bacteremia and/or meningitis, or it can occur alone. 

Isolated pneumococcal pneumonia is not considered an invasive disease, but it can be severe. It is estimated that 175,000 cases occur each year in the USA. The fatality rate is 5-7 percent and could be much higher in the elderly, says the CDC. Globally, pneumococcal pneumonia is estimated to cause about 500,000 deaths and 30 million episodes in adults 70 years and older annually.

Pneumococcal Vaccines

  • Pneumovax 23: is a vaccine that protects against infection by 23 types of pneumococcal bacteria, which are common and often cause serious illnesses.
  • Prevnar 13: is a vaccine that protects against invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
  • 20vPnC (PF-06482077): is a 20-Valent pneumococcal conjugate vaccine candidate to help protect from a substantial invasive pneumococcal disease and pneumonia burden. 

Pneumococcal Vaccine Candidates

Merck's V114, a phase 3 investigational 15-valent pneumococcal conjugate vaccine candidate.

Pneumococcal Pneumonia Research News

October 20, 2020 - Merck announced findings from two additional Phase 3 studies evaluating the safety, tolerability, and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine.

October 1, 2020 - US Health Officials Urge Influenza and Pneumococcal Vaccination Amid COVID-19 Pandemic.

September 30, 2020 - Study: Impact of 23‐valent pneumococcal polysaccharide vaccination on the frequency of pneumonia‐related hospitalization and survival in elderly patients with prostate cancer: A seven‐year nationwide matched cohort study.

September 27, 2020 - Study: Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany.

September 25, 2020 - The direct effect of pneumococcal conjugate vaccines on the invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006–17): a multicentre, retrospective observational study.

August 25, 2020 - The Lancet published: Assessing reduced-dose pneumococcal vaccine schedules in South Africa.

August 25, 2020 - Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomized, non-inferiority trial - The non-inferiority in post-booster immune responses following a single-dose compared with a 2-dose primary series of PCV13 or PCV10 indicates the potential for reducing PCV dosing schedules from a 2 + 1 to 1 + 1 series in low-income and middle-income settings with well-established PCV immunization programs.

August 10, 2020 - Study: Factors associated with pneumococcal vaccination uptake by cancer survivors.

July 31, 2020 - Can Flu and Pneumonia Vaccines Prevent Alzheimer’s Disease.

July 28, 2020 - The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis.

July 27, 2020 - Influenza and pneumonia vaccinations are associated with reduced risk of Alzheimer's disease, according to new research reported at the Alzheimer's Association International Conference 2020.

July 20, 2020 - Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.

July 15, 2020 - Serum Institute became the first research institute in India to manufacture a domestically developed, fully indigenously developed pneumococcal vaccine.

July 13, 2020 - The risk for invasive pneumococcal disease is increased when contracting influenza, but could be lessened in environments of high humidity, according to a study involving approximately 20,000 individuals in 3 countries, reported JAMA.

January 23, 2020 - Exposure to diesel exhaust particles linked to pneumococcal disease susceptibility.

Pneumococcal Indication

Pneumococcal Vaccines are indicated to prevent pneumococcal pneumonia that is the most common disease caused by a pneumococcal infection and can occur in combination with bacteremia and/or meningitis, or it can occur alone. 

Note: This content is reviewed by healthcare professionals such as Dr. Robert Carlson.

10/28/2020 - 10:45